Pinnacle West ( PNW) downgraded at Goldman from Neutral to Sell, Goldman Sachs said. $52 price target. Company has below-average earnings and dividend growth. Ventas ( VTR) downgraded at Jefferies to Hold from Buy, Jefferies said. $66 price target. Fiscal cliff looms.
STOCK COMMENTS / EPS CHANGES
Apache ( APA) estimates, target cut at Guggenheim. Shares of APA now seen reaching $111, according to Guggenheim. Estimates also reduced, given increased fleet downtime. Buy rating. Baker Hughes ( BHI) estimates cut at Dahlman through 2013, Dahlman Rose said. Company is leveraged to slower growth in North America. Buy rating and $50 price target. Peabody Energy ( BTU) numbers raised at Citigroup. Shares of BTU now seen reaching $33, Citigroup said. Estimates also increased on improving cost and capex management. Buy rating. Peabody Energy numbers boosted at Credit Suisse. Shares of BTU now seen reaching $33, according to Credit Suisse. Estimates also upped, as the company continues to execute well. Outperform rating. Caterpillar ( CAT) estimates, target cut at Credit Suisse. Shares of CAT now seen reaching $108, according to Credit Suisse. Estimates also reduced, given the company's new guidance. Outperform rating. Capital One ( COF) numbers raised at Guggenheim. Shares of COF now seen reaching $72, according to Guggenheim. Estimates also increased, as the company is realizing higher margins. Buy rating. Cognizant Technology ( CTSH) target raised at Oppenhiemer to $80, Oppenheimer said. Raising target ahead of quarterly results. Outperform rating. Freeport-McMoRan ( FCX) numbers cut at UBS. Shares of FCX now seen reaching $47, UBS said. Estimates also lowered as Grasberg guidance marginally lower. Buy rating. Freeport-McMoran numbers reduced at JP Morgan. Shares of FCX now seen reaching $63, according to JP Morgan. Estimates also cut, given lower realized gold volumes. Overweight rating. Forest Laboratories ( FRX) numbers cut at Morgan Stanley. FRX estimates were reduced through 2013, Morgan Stanley said. Company is seeing slower sales growth. Equal-weight rating and new $35 price target. Health Management ( HMA) numbers lowered at Credit Suisse. Shares of HMA now seen reaching $10, according to Credit Suisse. Estimates also cut, given weaker volumes and rising costs. Outperform rating.